Table 1 Direct links between circulating (dh)ceramides and cardiometabolic risk.

From: Dihydroceramide- and ceramide-profiling provides insights into human cardiometabolic disease etiology

 

T2D

CVD

(dh)ceramide

HR (95%CI)

HR (95%CI)

Cer16:0

–

1.53 (1.15, 2.02)

Cer18:0

1.98 (1.43, 2.74)

–

Cer20:0

0.59 (0.39, 0.9)

–

Cer22:0

2.77 (1.72, 4.47)

–

dhCer20:0

1.32 (1.08, 1.63)

–

dhCer22:2

1.32 (1.07, 1.62)

1.55 (1.23, 1.94)

dhCer26:1

0.86 (0.74, 0.99)

–

  1. Hazard ratio (HR) per one standard deviation higher plasma concentration in the EPIC-Potsdam cohort.
  2. Risk estimates are from a model that mutually included all ceramides selected as direct effectors by the NetCoupler-algorithm (see methods section), further adjusting for total ceramide and total dihydroceramide concentrations, age (strata variable), sex, height, waist circumference, leisure-time physical activity, fasting status, antihypertensive medication, lipid-lowering medication, aspirin, total energy intake, smoking, alcohol consumption, educational attainment, plasma concentrations of triglycerides, total cholesterol, and systolic and diastolic blood pressure; baseline-prevalent T2D cases were excluded from the diabetes risk model, and adjusted for in the CVD risk model.
Back to article page